S&P 500   4,610.89 (+0.14%)
DOW   36,328.18 (+0.22%)
QQQ   393.72 (+0.40%)
AAPL   192.16 (-1.81%)
MSFT   368.71 (-1.48%)
META   321.84 (-3.28%)
GOOGL   132.65 (-1.73%)
AMZN   144.47 (-2.00%)
TSLA   240.67 (-1.30%)
NVDA   462.83 (-2.57%)
NIO   7.44 (+0.81%)
BABA   71.15 (-1.37%)
AMD   132.95 (+3.13%)
T   16.58 (-2.01%)
F   11.09 (+0.73%)
MU   77.63 (+3.56%)
CGC   0.78 (-2.18%)
GE   120.23 (-0.30%)
DIS   92.60 (-0.24%)
AMC   6.81 (-1.73%)
PFE   28.52 (-0.90%)
PYPL   59.45 (+0.87%)
XOM   99.13 (-0.42%)
S&P 500   4,610.89 (+0.14%)
DOW   36,328.18 (+0.22%)
QQQ   393.72 (+0.40%)
AAPL   192.16 (-1.81%)
MSFT   368.71 (-1.48%)
META   321.84 (-3.28%)
GOOGL   132.65 (-1.73%)
AMZN   144.47 (-2.00%)
TSLA   240.67 (-1.30%)
NVDA   462.83 (-2.57%)
NIO   7.44 (+0.81%)
BABA   71.15 (-1.37%)
AMD   132.95 (+3.13%)
T   16.58 (-2.01%)
F   11.09 (+0.73%)
MU   77.63 (+3.56%)
CGC   0.78 (-2.18%)
GE   120.23 (-0.30%)
DIS   92.60 (-0.24%)
AMC   6.81 (-1.73%)
PFE   28.52 (-0.90%)
PYPL   59.45 (+0.87%)
XOM   99.13 (-0.42%)
S&P 500   4,610.89 (+0.14%)
DOW   36,328.18 (+0.22%)
QQQ   393.72 (+0.40%)
AAPL   192.16 (-1.81%)
MSFT   368.71 (-1.48%)
META   321.84 (-3.28%)
GOOGL   132.65 (-1.73%)
AMZN   144.47 (-2.00%)
TSLA   240.67 (-1.30%)
NVDA   462.83 (-2.57%)
NIO   7.44 (+0.81%)
BABA   71.15 (-1.37%)
AMD   132.95 (+3.13%)
T   16.58 (-2.01%)
F   11.09 (+0.73%)
MU   77.63 (+3.56%)
CGC   0.78 (-2.18%)
GE   120.23 (-0.30%)
DIS   92.60 (-0.24%)
AMC   6.81 (-1.73%)
PFE   28.52 (-0.90%)
PYPL   59.45 (+0.87%)
XOM   99.13 (-0.42%)
S&P 500   4,610.89 (+0.14%)
DOW   36,328.18 (+0.22%)
QQQ   393.72 (+0.40%)
AAPL   192.16 (-1.81%)
MSFT   368.71 (-1.48%)
META   321.84 (-3.28%)
GOOGL   132.65 (-1.73%)
AMZN   144.47 (-2.00%)
TSLA   240.67 (-1.30%)
NVDA   462.83 (-2.57%)
NIO   7.44 (+0.81%)
BABA   71.15 (-1.37%)
AMD   132.95 (+3.13%)
T   16.58 (-2.01%)
F   11.09 (+0.73%)
MU   77.63 (+3.56%)
CGC   0.78 (-2.18%)
GE   120.23 (-0.30%)
DIS   92.60 (-0.24%)
AMC   6.81 (-1.73%)
PFE   28.52 (-0.90%)
PYPL   59.45 (+0.87%)
XOM   99.13 (-0.42%)

REGENXBIO (RGNX) News Today

$19.26
-0.32 (-1.63%)
(As of 10:22 AM ET)
Compare
Today's Range
$19.02
▼
$19.67
50-Day Range
$12.89
▼
$20.60
52-Week Range
$12.82
▼
$25.54
Volume
17,881 shs
Average Volume
405,449 shs
Market Capitalization
$847.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$31.13
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability
SourceHeadline
MarketBeat logoREGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Brokerages
americanbankingnews.com - December 3 at 1:40 AM
finance.yahoo.com logoREGENXBIO Announces Dose Escalation in AFFINITY DUCHENNE® Trial
finance.yahoo.com - November 29 at 9:35 AM
finance.yahoo.com logoWall Street Analysts Believe Regenxbio (RGNX) Could Rally 95.61%: Here's is How to Trade
finance.yahoo.com - November 16 at 2:48 PM
finance.yahoo.com logoREGENXBIO (NASDAQ:RGNX) adds US$111m to market cap in the past 7 days, though investors from five years ago are still down 72%
finance.yahoo.com - November 12 at 9:51 AM
finance.yahoo.com logoREGENXBIO Inc. (NASDAQ:RGNX) Q3 2023 Earnings Call Transcript
finance.yahoo.com - November 9 at 5:30 PM
bizjournals.com logoRockville biotech RegenxBio to cut workforce by 15%, pursue strategic alternatives for several programs
bizjournals.com - November 9 at 12:29 PM
finanznachrichten.de logoREGENXBIO Inc.: REGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results
finanznachrichten.de - November 9 at 7:29 AM
marketwatch.com logoRegenxbio Cutting 15% of Staff, Exploring Strategic Alternatives
marketwatch.com - November 8 at 9:29 PM
finance.yahoo.com logoREGENXBIO Announces Updated Strategic Plans and Third Quarter 2023 Financial Results
finance.yahoo.com - November 8 at 4:28 PM
benzinga.com logoEarnings Preview For Regenxbio
benzinga.com - November 7 at 12:48 PM
finance.yahoo.com logoREGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
finance.yahoo.com - November 3 at 11:19 PM
msn.com logoRegenxbio: Biotech To Watch With 2 Possible Accelerated Approval Pathways
msn.com - November 2 at 8:01 PM
msn.com logoStifel Initiates Coverage of Regenxbio (RGNX) with Buy Recommendation
msn.com - November 2 at 10:00 AM
msn.com logoStifel starts Regenxbio at buy; cites broad platform, deep portfolio
msn.com - November 1 at 6:36 PM
finance.yahoo.com logoREGENXBIO to Host Conference Call on November 8 to Discuss Third Quarter 2023 Financial Results and Recent Operational Highlights
finance.yahoo.com - November 1 at 8:36 AM
finance.yahoo.com logoREGENXBIO Announces Presentations at the American Academy of Ophthalmology 2023 Annual Meeting
finance.yahoo.com - October 30 at 8:14 AM
seekingalpha.com logoRegenxbio: Promising Yet Risky Therapeutic Horizon
seekingalpha.com - October 25 at 6:05 AM
msn.com logoWedbush Reiterates Regenxbio (RGNX) Neutral Recommendation
msn.com - October 6 at 11:32 PM
markets.businessinsider.com logoPromising DMD Gene Therapy Results Bolster Buy Rating for RegenXBio: An Analysis of Brian Skorney’s Recommendation
markets.businessinsider.com - October 5 at 9:52 AM
finance.yahoo.com logoREGENXBIO to Participate in the Jefferies CNS/Neuro Summit
finance.yahoo.com - October 5 at 9:52 AM
markets.businessinsider.com logoHold Rating on REGENXBIO Amid Promising Yet Preliminary Duchenne Trial Results
markets.businessinsider.com - October 4 at 11:43 PM
seekingalpha.com logoRegenxbio up after hours on early-stage Duchenne candidate
seekingalpha.com - October 4 at 12:24 AM
seekingalpha.com logoOMEE, TNDM and RGNX are among after hour movers
seekingalpha.com - October 3 at 7:23 PM
finance.yahoo.com logoREGENXBIO Presents Interim Clinical Data from Phase I/II AFFINITY DUCHENNE™ Trial of RGX-202 at 28th Annual International Congress of the World Muscle Society
finance.yahoo.com - October 3 at 7:23 PM
finance.yahoo.com logoREGENXBIO Announces Presentations at the 28th Annual Congress of the World Muscle Society
finance.yahoo.com - September 26 at 8:26 AM
finance.yahoo.com logoWe're Keeping An Eye On REGENXBIO's (NASDAQ:RGNX) Cash Burn Rate
finance.yahoo.com - September 22 at 1:31 PM
marketbeat.com logoREGENXBIO Inc. (NASDAQ:RGNX) Shares Purchased by Harbor Capital Advisors Inc.
marketbeat.com - September 19 at 6:38 AM
marketbeat.com logoREGENXBIO Inc. (NASDAQ:RGNX) Given Average Recommendation of "Moderate Buy" by Analysts
marketbeat.com - September 19 at 2:41 AM
marketbeat.com logoCitigroup Inc. Purchases 34,856 Shares of REGENXBIO Inc. (NASDAQ:RGNX)
marketbeat.com - September 6 at 4:41 AM
finance.yahoo.com logoREGENXBIO Inc. (RGNX) Stock Historical Prices & Data - Yahoo Finance
finance.yahoo.com - September 5 at 4:10 AM
marketbeat.com logoRussell Investments Group Ltd. Acquires 51,116 Shares of REGENXBIO Inc. (NASDAQ:RGNX)
marketbeat.com - September 1 at 4:21 AM
finance.yahoo.com logoInitial Clinical Data of First Pediatric CLN2 Patient Dosed with RGX-181 Presented at SSIEM Annual Symposium
finance.yahoo.com - August 30 at 4:56 PM
marketbeat.com logoREGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by Analysts
marketbeat.com - August 25 at 2:36 AM
finance.yahoo.com logoREGENXBIO Announces Presentations at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2023
finance.yahoo.com - August 23 at 4:51 PM
marketbeat.com logoBarclays PLC Sells 29,860 Shares of REGENXBIO Inc. (NASDAQ:RGNX)
marketbeat.com - August 21 at 4:34 AM
marketbeat.com logoJupiter Asset Management Ltd. Makes New Investment in REGENXBIO Inc. (NASDAQ:RGNX)
marketbeat.com - August 18 at 6:38 AM
marketbeat.com logoREGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Victory Capital Management Inc.
marketbeat.com - August 15 at 4:46 AM
seekingalpha.com logoRegenxbio: RGX-314 Continues Advancing With Solid Financials
seekingalpha.com - August 10 at 1:23 AM
marketbeat.com logoLos Angeles Capital Management LLC Has $368,000 Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)
marketbeat.com - August 9 at 6:12 AM
marketbeat.com logoREGENXBIO Inc. to Post Q3 2023 Earnings of ($1.26) Per Share, Leerink Partnrs Forecasts (NASDAQ:RGNX)
marketbeat.com - August 7 at 2:25 AM
markets.businessinsider.com logoRBC Capital Sticks to Its Hold Rating for RegenXBio (RGNX)
markets.businessinsider.com - August 5 at 1:14 AM
marketbeat.com logoRoyce & Associates LP Has $3.45 Million Holdings in REGENXBIO Inc. (NASDAQ:RGNX)
marketbeat.com - August 4 at 5:58 AM
msn.com logoChardan Capital Reiterates Regenxbio (RGNX) Buy Recommendation
msn.com - August 4 at 3:35 AM
finance.yahoo.com logoRegenxbio Inc (RB0.MU)
finance.yahoo.com - August 3 at 5:09 PM
markets.businessinsider.com logoAnalysts’ Opinions Are Mixed on These Healthcare Stocks: RegenXBio (RGNX) and Intercept Pharma (ICPT)
markets.businessinsider.com - August 3 at 11:57 AM
finance.yahoo.com logoREGENXBIO Announces Participation at the 2023 Wedbush PacGrow Healthcare Conference
finance.yahoo.com - August 1 at 9:11 PM
marketbeat.com logoREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by Brokerages
marketbeat.com - July 31 at 1:48 AM
finance.yahoo.com logoREGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights
finance.yahoo.com - July 27 at 12:20 AM
finance.yahoo.com logoREGENXBIO Announces Upcoming Presentations at the American Society of Retina Specialists Annual Scientific Meeting
finance.yahoo.com - July 24 at 9:00 PM
marketbeat.com logoJennison Associates LLC Reduces Stock Position in REGENXBIO Inc. (NASDAQ:RGNX)
marketbeat.com - July 17 at 5:26 AM
Get REGENXBIO News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.



RGNX Media Mentions By Week

RGNX Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

RGNX
News Sentiment
▼
0.00

0.53
▲
Average
Medical
News Sentiment

RGNX News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

RGNX Articles
This Week
▼
0

2
▲
RGNX Articles
Average Week

Get REGENXBIO News Delivered to You Automatically

Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools

Related Companies:
Headlines Tools:
This page (NASDAQ:RGNX) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -